REG - Oxford Biomedica PLC - Dr Frank Mathias to join as new CEO on 27 March

Oxford BioMedicaAnnouncement

20/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230220:nRST3622Qa&default-theme=true

RNS Number : 3622Q  Oxford Biomedica PLC  20 February 2023

 

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

-       Dr Mathias brings a wealth of experience in innovation, contract
development and manufacturing to Oxford Biomedica

-       Stuart Henderson to take on newly created position of Vice Chair
and Dame Kay Davies to become Senior Independent Director

 

Oxford, UK - 20 February 2023: Oxford, UK - Oxford Biomedica (LSE:OXB), a
leading gene and cell therapy group, today announces that Dr Frank Mathias
will officially join Oxford Biomedica as Chief Executive Officer (CEO) and
Board member on Monday, 27th March 2023. His appointment was previously
announced
(https://www.oxb.com/news-media/press-release/oxford-biomedica-appoints-dr-frank-mathias-chief-executive-officer)
on 22nd November 2022.

Dr Frank Mathias joins Oxford Biomedica from Rentschler Biopharma SE
("Rentschler") where he has been CEO since 2016. He successfully transformed
Rentschler into a leading global, full-service CDMO and transformed the
financials of the business including a three-fold increase in revenue, while
also improving efficiencies and profitability at an even faster rate.

Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: "We are
extremely excited about the imminent arrival of Frank as our new CEO. Frank
brings a wealth of experience in innovation, contract development and
manufacturing to Oxford Biomedica and I feel, with Frank's new leadership, we
are extremely well-positioned to deliver the growth and full potential of the
company given our leading technology. As a viral vector leader, Oxford
Biomedica is poised to build its position as a world-class, innovation-led
CDMO delivering life-changing therapies to patients."

Dr Frank Mathias, incoming Chief Executive Officer, said: "I look forward to
joining Oxford Biomedica and leading the Company in its mission to deliver
innovative services to biopharma customers, enabling them to discover and
deliver therapies that transform patients' lives. Oxford Biomedica has a clear
vision for the future, and I believe it has great potential to become the
leader in the viral vector CDMO market. I firmly believe in the Company's
strategy for growth and am excited to start working towards our goal to
deliver products to patients as quickly as possible."

In addition, Oxford Biomedica announces two changes to its Board, both of
which will also take effect on 27(th) March 2023. Stuart Henderson will become
Vice Chair, a newly created position which replaces the previously combined
role of Deputy Chair and Senior Independent Director, the position Stuart has
filled since June 2020. Professor Dame Kay Davies will assume the role of
Senior Independent Director, following her appointment as a Non-Executive
Director in March 2021.

 

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Cole            / Matthew Neal

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUMCPUPWGBB